早产儿视网膜病变抗血管内皮生长因子治疗的最新进展
An Update on Anti-Vascular Endothelial Growth Factor Treatment for Retinopathy of Prematurity.
作者信息
Nowroozzadeh M Hossein, Sadeghi Elham, Shahriari-Garaee Hossein, Badie Mohammad Reza, Banihashemi Javad, Garg Sunir J
机构信息
Department of Ophthalmology, Shiraz University of Medical Sciences, Shiraz, Iran.
Department of Ophthalmology, University of Pittsburgh, School of Medicine, Pittsburgh, PA, USA.
出版信息
J Curr Ophthalmol. 2023 Dec 21;35(2):125-134. doi: 10.4103/joco.joco_38_23. eCollection 2023 Apr-Jun.
PURPOSE
To present updated information on the role of anti-vascular endothelial growth factor (anti-VEGF) therapy for treating retinopathy of prematurity (ROP).
METHODS
We searched through PubMed and Scopus databases using the keywords of this article and gathered relevant published articles from the year 2005 to December 2022. The selected articles were classified and summarized, and reasonable conclusions were made accordingly.
RESULTS
Considering the current evidence, anti-VEGF agents are superior to laser therapy for the initial treatment of type 1 ROP in zone 1 or posterior zone 2. However, there is a substantial risk of reactivation or persistent avascular retina after solo treatment with anti-VEGFs, and many cases may require laser therapy within the following weeks or months. Thus, vigilant follow-up examinations are mandatory.
CONCLUSIONS
The role of anti-VEGF agents in the treatment of ROP is indispensable. However, future studies are required to improve indications and dosage and determine long-term ocular and systemic safety.
目的
提供关于抗血管内皮生长因子（抗VEGF）疗法在治疗早产儿视网膜病变（ROP）中作用的最新信息。
方法
我们使用本文关键词在PubMed和Scopus数据库中进行检索，并收集了2005年至2022年12月期间发表的相关文章。对所选文章进行分类和总结，并据此得出合理结论。
结果
根据目前的证据，抗VEGF药物在初始治疗1区或2区后部的1型ROP方面优于激光治疗。然而，单独使用抗VEGF治疗后，视网膜再激活或持续性无血管化的风险很大，许多病例可能在接下来的几周或几个月内需要激光治疗。因此，必须进行密切的随访检查。
结论
抗VEGF药物在ROP治疗中的作用不可或缺。然而，未来需要开展研究以改进适应证和剂量，并确定长期的眼部和全身安全性。
Zotero 插件